Kornimate/medical-research-clean huggingface dataset:
aza combined with r-gemox for elderly dlbcl patients

Conditions: DLBCL - Diffuse Large B Cell Lymphoma

Summary: this is a prospective, single-arm, multicenter, phase ii clinical trial to evaluate the efficacy and safety of aza（azacytidine）combined with the r-gemox (rituximab, gemcitabine and oxaliplatin) regimen as first-line treatment in elderly diffuse large b-cell lymphoma (dlbcl) patients.

the purpose of this phase ii clinical trial is to evaluate the efficacy and safety of aza in combination with r-gemox for untreated elderly dlbcl patients. the induction phase consisted of 8 cycles of aza in combination with r-gemox for a total of 8 treatment cycles. the efficacy was evaluated every 4 cycles, and if the efficacy was evaluated as complete remission (cr) or partial remission (pr), the original chemotherapy regimen was continued for 4 courses. if efficacy was assessed as stable disease (sd) or progressive disease (pd), the study was withdrawn.after 8 cycles of induction therapy, if the response is assessed as cr or pr, patients may end treatment or receive rituximab maintenance therapy. the primary endpoint is the overall response rate (orr).secondary efficacy measures included cr and pr,sd, progression-free survival (pfs) and overall survival (os).

Eligibility criteria:
key inclusion criteria: 1. subjects fully understand and voluntarily participate in this study and sign informed consent. 2. aged ≥60 years, both male and female. 3. pathologically confirmed dlbcl 4. there must be at least one measurable or evaluable lesion that meets the evaluation criteria for lugano 2014 lymphoma. 5. no previous chemotherapy or radiotherapy for dlbcl has been received. 6. expected survival ≥3 months. key exclusion criteria: 1. dlbcl combined with other types of lymphoma. transformed dlbcl. 2. dlbcl with central nervous system invasion. 3. the patients have contraindications to any drug in the combined treatment. 4. patients with the infection of human immunodeficiency virus (hiv) and/or acquired immunodeficiency syndrome. 5. mentally ill persons or persons unable to obtain informed consent. 6. the investigators think that the patient is not suitable for the study.

Keywords: diffuse large b-cell lymphoma gemox r aza
neurobiology of language recovery in aphasia: natural history and treatment-induced recovery

Conditions: Aphasia; Dysgraphia; Anomia; Agrammatism; Stroke

Summary: the purpose of this study is to investigate the effects of treatment for specific language deficits in people with aphasia. in addition to language and cognitive measures, changes in brain function will also be gathered before and after the treatment is administered in order to track any changes resulting from receiving treatment.

naming impairments (anomia): the labs of dr. swathi kiran (boston university) and dr. david caplan (harvard university, massachusetts general hospital) will be studying language recovery in adults with anomia (naming impairments) following a stroke. participants will receive treatment focusing on the semantic features of common objects (e.g., that birds can fly). the study will examine how naming and other language abilities change in response to treatment, as well as how the brain changes, as measured by magnetic resonance imaging (mri) and other techniques. spelling/writing impairments (dysgraphia): at johns hopkins university, the lab of dr. brenda rapp will investigate the neurobiology of language recovery in individuals with dysgraphia (spelling/writing impairments) resulting from a stroke. in this study, treatment will focus on improving spelling ability. the study will examine how spelling and other language abilities change in response to treatment, as well as how the brain changes, as measured by magnetic resonance imaging (mri) and other techniques. deficits in sentence comprehension \& production: dr. cynthia thompson's lab at northwestern university will investigate language recovery in individuals with deficits in sentence production and comprehension. treatment focuses on production and comprehension of complex sentences. at baseline (week 0) and after the treatment period (at week 12), participants take part in language, eye-tracking, and mri testing, in order to learn how the processing of language, as well as brain function, changes as a result of treatment.

Eligibility criteria:
inclusion criteria: * aphasia following a stroke * stoke was at least 1 year ago * medically stable * right-handed * normal or 'corrected to normal' vision and hearing * english as primary language * at least a high school education exclusion criteria: * history of neurological disease, head trauma, psychiatric disorders, alcoholism, or developmental speech, language, or learning disabilities

Keywords: aphasia dysgraphia anomia agrammatism stroke language recovery treatment biomarkers of recovery
a study of special use results surveillance of revlimid 5mg capsules

Conditions: Multiple Myeloma; Myelodysplastic Syndromes

Summary: to understand the safety and efficacy of revlimid® 5 mg capsules (hereinafter referred to as revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1. planned registration period this period started on the date of initial marketing of revlimid and will end at the time when the planned number of patients to be enrolled is reached. 2. planned surveillance period this period started on the date of initial marketing of revlimid and will end on the day when the approval condition related to all-case surveillance is terminated.


Eligibility criteria:
inclusion criteria: * among relapsed or refractory multiple myeloma and myelodysplastic syndrome (mds) with a deletion 5q cytogenetic abnormality patients, all patients who received revlimid will be targeted in this surveillance. exclusion criteria: n/a

Keywords: teratogenicity thrombocytopenia and haemorrhage neutropenia and infection venous thromboembolism allergic reactions diarrhoea or constipation peripheral neuropathy cardiac failure arrhythmia renal failure myocardial infarction interstitial lung disease tumour lysis syndrome transformation from myelodysplastic syndrome to acute myeloid leukemia
cardiovascular risk and identification of potential high-risk population in acute myocardial infarction ii (corea-ami ii)

Conditions: Acute Myocardial Infarction; Percutaneous Coronary Intervention; Major Adverse Cardiovascular Events; Bleeding

Summary: this study is intended to provide contemporary data on the residual cardiovascular risk in all consecutive patients with acute myocardial infarction, especially in patients who survived stably within one-year after percutaneous coronary intervention. in addition, this study will identify which baseline clinical, angiographic, or treatment factors are associated with residual cardiovascular risk and bleeding events

corea-ami registry was conducted previously (nct02385682) and enrolled consecutive all patient with acute myocardial infarction who were treated with percutaneous coronary intervention from jan 2004 to dec 2009. corea-ami ii registry extend the enrollment period to aug 2014 and the follow-up period to jun 2016. all consecutive acute myocardial infarction patients had been enrolled prospectively in prior registries of each university hospitals. eight hospitals of the catholic university of korea already have web-based coronary intervention registry (nct01239914). and cheonnam university hospital is one of leading hospitals to design and manage the web-based previous korean nationwide myocardial infarction registry, the korea acute myocardial infarction registry (kamir) (http://www.kamir.or.kr/). using these previous data, the current registry update new clinical and angiographic variables and assess long-term clinical follow-up data retrospectively. all data were collected on web-based system after eliminating personal information. (http://www.ecrf.kr/coreaami/) all data are going to be sealed with code by clinical research coordinating center of the catholic university of korea and to be managed and analyzed by independent statistics perssonels. cardiovascular center with high-volume percutaneous coronary intervention of following hospitals were participated. * seoul st. mary's hospital, seoul, south korea * yeoido st. mary's hospital, seoul, south korea * uijongbu st. mary's hospital, gyeonggi-do, south korea * st. paul hospital, seoul, south korea * bucheon st. mary's hospital, gyeonggi-do, south korea * incheon st. mary's hospital, incheon, south korea * st. vincent hospital, gyeonggi-do, south korea * deajon st. mary's hospital, daejeon, south korea * cheonnam university hospital, gwangju, south korea

Eligibility criteria:
inclusion criteria: * acute myocardial infarction who were treated with percutaneous coronary intervention using stents exclusion criteria: * acute myocardial infarction who were treated with only balloon angioplasty * acute myocardial infarction who were managed by conservative strategy
recovery housing for drug dependent pregnant women

Conditions: Drug Addiction

Summary: for the past several years our research program has developed and tested an intensive outpatient intervention that is based in social learning theory and employs abstinence contingent access to recovery housing as a routine aspect of an intensive day treatment counseling program. the present project proposes to extend this treatment intervention to the special population of pregnant drug using women enrolled at the center for addiction and pregnancy (cap). we will compare an enhanced treatment that includes abstinence contingent recovery house living plus intensive individual therapy, to standard care at the cap program. specific aims of the project are derived from testing a two-group design are described below: 1. to determine whether financially supported abstinence-contingent recovery house placement plus individual counseling in pregnant drug-dependent women improves prenatal outpatient treatment retention. 2. to determine whether financially supported abstinence-contingent recovery house placement plus individual counseling in pregnant drug-dependent women reduces prenatal drug use. 3. to determine whether financially supported abstinence-contingent recovery house placement plus individual counseling results in better maternal and infant clinical birth outcomes (e.g., birth weight, estimated gestational age (ega) at delivery, medical complications).


Eligibility criteria:
inclusion criteria: * cap enrolled * age 18 or older * evidence of use of opiate and/or cocaine use in the past 30 days * assigned to pharmacotherapy free modality * cap admission at an estimated gestational age (ega) \<34 weeks exclusion criteria: * endorses current suicidal ideation * any medical disorders requiring extended or future hospitalization * meet diagnostic criteria for current dsm-iv alcohol dependence * meet diagnostic criteria for a current dsm-iv axis i thought disorder (i.e. schizophrenia) * demonstrate significant cognitive impairment that precludes them from completing the initial assessment battery

Keywords: cocaine opiate pregnancy post-partum neonatal abstinence syndrome contingency management reinforcement based treatment women
"a study to assess knowledge and opinion regarding adoption among adults residing in rural and urban area"

Conditions: Knowledge

Summary: a cross - sectional comparative study to assess knowledge and opinion regarding adoption among adults residing in rural and urban area of ambala, haryana.

abstract introduction: children are regarded as the precious gift in world. it is estimated that between 8% and 12% of couples worldwide suffer from infertility with rate of 10% in india and about 20 million children are orphan even then adoption rates are falling in india. objectives: to assess and compare the knowledge score and opinion score regarding adoption among adults of different age groups.to determine relationship between knowledge and opinion regarding adoption among adults.to seek association of knowledge score and opinion score regarding adoption with selected variables. methodology: a descriptive cross sectional survey design was used. 400 adults of rural (200) and urban (200) area were selected by using quota sampling technique. the data was collected by structured knowledge questionnaire and structured likert scale.

Eligibility criteria:
inclusion criteria: * adults who were able to understand hindi and english. * who were willing to participate in the study. exclusion criteria: * adults who were not available at the time of data collection. * adults having any psychological impairment.

Keywords: knowledge opinion adoption adults cross-sectional
macular ganglion cell analysis (gca) of the cirrus hd-oct in glaucoma

Conditions: Glaucoma

Summary: to determine the area under the receiver operator characteristic curve (auc) for the ganglion cell analysis (gca) average thickness.

to determine the area under the receiver operator characteristic curve (auc) for the following gca parameters: 1. minimum thickness 2. supero-temporal thickness 3. superior thickness 4. supero-nasal thickness 5. infero-temporal thickness 6. inferior thickness 7. infero-nasal thickness

Eligibility criteria:
inclusion criteria: * age of 40 years or older * diagnosed to have glaucoma by the principal investigator or co-investigator * able and willing to make the required study visits * able and willing to give consent and follow study instructions exclusion criteria: ophthalmic: * best corrected visual acuity in either eye worse than 20/40 on a snellen chart or on a snellen equivalent acuity chart. * refractive error outside -12.00d to +8.00d spherical range or \>-3.00d cylinder. * previous vitreoretinal surgery in study eye. * vitreoretinal traction or epiretinal membrane in the study eye. * any active infection of anterior or posterior segments. * evidence of diabetic retinopathy, diabetic macular edema, or other vitreoretinal disease in the study eye upon dilated examination, or upon evaluation of retinal photos. systemic: * history of diabetes, leukemia, aids, uncontrolled systemic hypertension, dementia or multiple sclerosis. * a life threatening or debilitating disease. * participation in any study involving a non-fda approved investigational drug (ind) within the past month, or ongoing participation in a study with a non-fda approved or cleared investigational device (ide). * current or recent (within the past 14 days) use of an agent with photosensitizing properties by any route (e.g., visudyne®, ciprofloxacin, bactrim®, doxycycline, etc.). * concomitant use of hydrochloroquine and/or chloroquine.
single-cell sequencing analysis of resectable/borderline resectable pancreatic cancer patients

Conditions: Pancreatic Neoplasms

Summary: preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (brpc). however, there are limitations in this field. treatment strategies and definitions for brpc patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.this study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.


Eligibility criteria:
inclusion criteria: * 18 years ≤ age ≤ 75 years. * resectable/borderline resectable pancreatic cancer patients diagnosed based on pathological and preoperative imaging evaluation. * no prior history of any form of anti-tumor treatment. * at least one measurable lesion. * eastern cooperative oncology group (ecog): 0-1. * not participated in any other clinical studies before or during treatment. * willingness to participate voluntarily in this study, signing an informed consent form. exclusion criteria: * history of any other malignant tumor, except for completely resected basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, within the past 5 years. * vaccination with live vaccines within 4 weeks prior to enrollment or during the study period. * active autoimmune diseases or a history of autoimmune diseases within the past 4 weeks before enrollment. * allogeneic bone marrow or organ transplantation. * active gastric or duodenal ulcers, ulcerative colitis, or active bleeding from unresected tumors in the gastrointestinal tract, or other conditions determined by the investigator that may cause gastrointestinal bleeding or perforation. * evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding \>30 ml within 3 months, hematemesis, melena, or hematochezia), hemoptysis (\>5 ml of fresh blood within 4 weeks), or occurrence of thromboembolic events within 12 months (including stroke events and/or transient ischemic attacks).

Keywords: pancreatic neoplasms single-cell sequencing immune microenvironment
japanese phase 1 multiple ascending dose study

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of bms-823778 in healthy japanese subjects and japanese patients with type 2 diabetes mellitus.

mad study - multiple ascending dose study

Eligibility criteria:
inclusion criteria: * japanese patients with type 2 diabetes mellitus (t2dm) \[fasting glucose \< 240 mg/dl, hemoglobin a1c (hba1c): 6.5% to 10.0% national glycohemoglobin standardization program (ngsp)\] who are treatment-naive and managed with diet and/or exercises only, ages: 20 to 65 years exclusion criteria: * patient who is taking any medication for t2dm * symptoms of poorly controlled diabetes that would preclude participation in this placebo-controlled trial * insulin therapy within one year of screening
effectiveness of cognitive behavioral treatment and mindfulness based stress reduction (mbsr) for chronic low back pain

Conditions: Chronic Low Back Pain

Summary: the primary purpose of this study is to determine the effectiveness of two psychological techniques in chronic low back pain patients treated in hospital pain clinics. the techniques are: cognitive behavioral treatment and mindfulness based stress reduction (mbsr). this is a multiple site project in which patients come from 16 different pain clinics throughout spain. the control group is formed by patients under usual medical treatment at pain clinics. the two intervention groups also receive usual medical treatment at pain clinics plus one psychological therapy treatment. the sample size is 330 subjects.


Eligibility criteria:
inclusion criteria: * chronic low back pain and failed back surgery patients * with or without referred or radiated pain * who are between 18 and 70 years of age (inclusive) exclusion criteria: * patients with red flags for systemic disease or criteria for surgery * with intolerable intensity of pain despite 6 weeks or more of non-surgical treatment * with pain that appears only on walking and disappears with sitting, persists after 6 months of conservative treatment, and is a possible spinal stenosis * under psychological or psychiatric treatment * unable to fill out the questionnaires * have received cognitive behavioral treatment in the past * have ongoing work litigation or are in the process of obtaining permanent disability.

Keywords: chronic low back pain cognitive-behavioral therapy mindful based stress reduction pain clinics anxiety quality of life chronic pain
exploratory study evaluating fluorodeoxyglucose - position emission tomography as a predictive marker for therapy with rad001 in metastatic renal cell cancer

Conditions: Carcinoma, Renal Cell

Summary: the purpose of this study is to learn if pet scanning can predict the degree of tumor shrinkage with the study drug rad001 in subjects who have advanced renal cancer.


Eligibility criteria:
inclusion criteria: * metastatic renal cancer refractory to sorafenib or sunitinib therapy * at least one measurable site of disease according to recist criteria that has not been previously irradiated. * 18 years of age or older * minimum of two weeks since any major surgery, completion of radiation, or completion of all prior standard systemic anticancer therapy and adequately recovered from the acute toxicities of any prior therapy. * world health organization (who) performance status \<= 2 * adequate bone marrow function * adequate liver function * adequate creatinine clearance * signed informed consent exclusion criteria: * prior treatment with any investigational drug within the previous 4 weeks * chronic treatment with systemic steroids or another immunosuppressive agent * uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases * patients who have a history of another primary malignancy ≤ 3 years, with the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix * patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study * a known history of hiv seropositivity * impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of rad001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) * patients with an active, bleeding diathesis or on oral anti-vitamin k medication * women who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth control from enrollment through 6 months following the end of treatment * patients who have received prior treatment with an mtor inhibitor. * patients with a known hypersensitivity to rad001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients * history of noncompliance to medical regimens * patients unwilling to or unable to comply with the protocol

Keywords: metastatic renal cell carcinoma cancer
renal magnetic resonance angiography (mra) study comparing dotarem and time of flight (tof)

Conditions: Renal Artery Stenosis

Summary: the study will evaluate the efficacy and safety of dotarem enhanced mra compared to tof mra in patients suffering from renal arterial disease.

each participant will undergo first a tof mra followed by a dotarem-enhanced mra.

Eligibility criteria:
inclusion criteria: * male or female, aged more than 18 years, * strongly suspected of having renal arterial disease, * scheduled (or to be scheduled) to undergo arterial catheter-based x-ray angiography examination, exclusion criteria: * known grade iv or v chronic kidney disease (gfr\<30 ml/min/1.73m²), * contraindication to mri, * acute renal dysfunction within the 6 months preceding dotarem®-enhanced mra examination,

Keywords: renal artery stenosis contrast agent mra